Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FCER2 | P06734 | 4/20 | 0.48 |
| ▸ | MMP3 | P08254 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.47 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.45 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | CPA1 | P15085 | 1/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4678251 | 0.86 | FCER2 (0.49) | FCER2MMP3MMP9OPRD1KISS1R | |
| SCHEMBL4683247 | 0.86 | FCER2 (0.49) | FCER2MMP3MMP9OPRD1KISS1R | |
| SCHEMBL30995920 | 0.78 | FCER2 (0.63) | FCER2MMP3MMP9OPRD1MME | |
| SCHEMBL13538441 | 0.77 | FCER2 (0.55) | FCER2MMP3MMP9 | |
| SCHEMBL4680362 | 0.76 | KISS1R (0.47) | FCER2MMP3MMP9KISS1RMME | |
| SCHEMBL4680502 | 0.76 | KISS1R (0.47) | FCER2MMP3MMP9KISS1RMME | |
| SCHEMBL21930739 | 0.75 | OPRD1 (0.53) | FCER2MMP9OPRD1MMEACE | |
| SCHEMBL4675732 | 0.74 | KISS1R (0.49) | FCER2MMP3MMP9KISS1R | |
| SCHEMBL4680626 | 0.74 | FCER2 (0.51) | FCER2MMP3MMP9OPRD1KISS1R | |
| SCHEMBL4682112 | 0.74 | FCER2 (0.51) | FCER2MMP3MMP9OPRD1KISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1975153-A2 | Protease inhibitors | Prozymex A/S (DK) | 2008-10-01 | — | — | EP | disclosed |
| EP-1633702-B1 | PROTEASE INHIBITORS | PROZYMEX AS (DK) | 2008-07-02 | — | — | EP | disclosed |
| US-20070155803-A1 | Protease inhibitors | PROZYMEX A/S (DK) | 2007-07-05 | — | — | US | disclosed |
| US-20070155803-A1 | Protease inhibitors | PROZYMEX A/S (DK) | 2007-07-05 | — | — | US | disclosed |
| WO-2004106289-A1 | PROTEASE INHIBITORS | PROZYMEX A/S (DK) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155803-A1 | Protease inhibitors | DPP7, DPP9, DPP3 | FCER2 588/4885MMP3 33/4885MMP9 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.